Safety, Pharmacokinetics, and Efficacy of 1.5% Ruxolitinib Gel (HDM3010) in Adult Patients with Prurigo Nodularis: A Phase I/II, Randomized, Double-Blind, Vehicle-Controlled Multicenter Clinical Trial

Abstract Introduction Prurigo nodularis (PN) is a chronic inflammatory dermatosis with severe, persistent pruritus and limited effective therapies. Janus kinase (JAK) inhibition has emerged as a targeted strategy for PN. Methods This phase I/II, randomized, double-blind, vehicle-controlled, multicen...

Бүрэн тодорхойлолт

Номзүйн дэлгэрэнгүй

Үндсэн зохиолчид:	Chao Wu, Xuping Niu, Xiaohua Wang, Juan Su, Hengguang Zhao, Mao Lin, Chunjun Yang, Xiaoming Qin, Shuping Guo, Cunhuo Jiang, Hui Tang, Haijing Yang, Liming Wu, Min Zhu, Aihua Wei, Xiaohua Tao, Yiwen Zhang, Chang Shu, Jiawei Liu, Lu Yang, Yuetong Qian, Bingjie Zhang, Shiyu Zhang, Junfang Xu, Yang Lu, Mingjia Peng, Shizheng Luo, Weijie Ma, Hongzhong Jin
Формат:	Artigo
Хэл сонгох:	Inglês
Хэвлэсэн:	Adis, Springer Healthcare 2026-05-01
Цуврал:	Dermatology and Therapy
Нөхцлүүд:	Prurigo nodularis JAK inhibitor Ruxolitinib gel Safety Pharmacokinetics Efficacy
Онлайн хандалт:	https://doi.org/10.1007/s13555-026-01787-x
Шошгууд:	Шошго нэмэх Шошго байхгүй, Энэхүү баримтыг шошголох эхний хүн болох!